Chinese Drug Development Firm Ribo Completes $28M Series C1 Round

Suzhou Ribo Life Science Co. Ltd. (Ribo), a siRNA drug development company in China, announced today that it has raised RMB203 million (US$28.78 million) in a series C1 round of financing led by Panlin Capital and Trinity Innovation Fund.

China Money Network

Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech

Register Now

Want to read this important story?

Access thousands of news articles and data posts over the past 9 years!

Already have an account or paid subscription? Log in

Caishen.Co - Primary Data for China Secondary Investment and Stock Markets